Prognostic impact of unfavorable cytogenetic abnormalities in
multiple myeloma patients treated by bortezomib (velcade)

D 2007

Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Petr KUGLÍK et. al.

Základní údaje

Originální název

Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)

Název česky

Prognostický vliv cytogenetických abnormalit u pacientů s mnohočetným myelomem léčených bortezomibem (Velcade)

Autoři

NĚMEC, Pavel (203 Česká republika), Henrieta GREŠLIKOVÁ (703 Slovensko), Romana ZAORALOVÁ (203 Česká republika), Hana FILKOVÁ (203 Česká republika), Petr KUGLÍK (203 Česká republika), Alexandra OLTOVÁ (203 Česká republika), Luděk POUR (203 Česká republika), Zdeněk ADAM (203 Česká republika), Andrea KŘIVANOVÁ (203 Česká republika), Marta KREJČÍ (203 Česká republika) a Roman HÁJEK (203 Česká republika, garant)

Vydání

Volume 92, no. 6 supplement. Pavia, Italy, Hematologica/The Hematology Journal, od s. 165-165, 1 s. 2007

Nakladatel

Ferrata-Storti Foundation

Další údaje

Jazyk

angličtina

Typ výsledku

Stať ve sborníku

Obor

Genetika a molekulární biologie

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.516

Kód RIV

RIV/00216224:14110/07:00022796

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000247425800331

Klíčová slova anglicky

multiple myeloma; 1q21 amplifiaction; Velcade; fluorescence in situ hybridisation; DNA probe

Štítky

1q21 amplifiaction, DNA probe, fluorescence in situ hybridisation, multiple myeloma, Velcade

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 3. 2009 11:06, Mgr. Pavel Němec, Ph.D.

Anotace

ORIG CZ

V originále

i) Introduction: The aim of this study is to investigate if Bortezomib (Velcade) is able to antagonize the impact of negative cytogenetic prognostic markers. We have focused on four chromosomal aberrations known as negative prognostic factors in multiple myeloma (MM) treated by conventional or myeloablastive treatment: deletion of RB gene (13q14), deletion of p53 (17p13), amplification of CKS1B gene (1q21) and translocation t(4;14). ii) Material and Methods: We have identified monotypic plasma cells and studied chromosomal aberrations by cytoplasmic light-chain fluorescence in situ hybridization (cIg-FISH) technique. Up-to-date group of 18 patients (pts.) has following characteristic: 67% of men, median age 62,5 years (44,4-77,9). 50% (9 pts.) were in stage IIIA, 28% (5 pts.) in IIA and 22% (4 pts.) in IA. 61% (11 pts.) were in first relapse, 22% (4 pts.) were in second relapse. The others 17% (3 pts.) were in third relapse. Treatment with Velcade based regimens was continued for up to 8 cycles in 66 % pts. (12/18). ii) Preliminary results: Cytogenetic findings: Deletion of RB gene was found in 8/16 (50%) pts., t(4;14) in 8/15 (53%) pts., deletion of p53 gene in 7/15 (47%) cases and amplification of CKS1B gene in 10/15 pts. (66%). Overall Response (OR) was 39% (0% CR, 11% VGPR, 28% PR). OR was not higher in pts. with cytogenetic findings for all aberration types except t(4;14): OR was 38% vs. 38% for pts. with vs. without deletion of RB gene; 63% vs. 14% for t(4;14) (p=0,240); 29% vs. 50% for deletion of p53 and 40% vs. 40% for amplification of CKS1B. Further, Velcade based therapy showed comparable TTP, DOR and OS in pts. with or without cytogenetic aberations including t(4;14). iv) Preliminary conclusions: We have found no significant difference when compared positivity vs. negativity of each cytogenetic aberration (including t(4;14)) for OR, TTP, DOR, PFS, and OS. This should have been caused by small size of our sample. It is possible that Velcade antagonizes the negative prognostic value of studied cytogenetic findings in MM. Supported by Myeloma Basic Research Centre Brno MU (LC 06027) and by grant from Ministry of Educations MSM0021622415.

Česky

Práce pojednává o významu detekce chromozomálních aberací u pacientů s mnohočetným myelomem léčených bortezomibem (Velcade).

Návaznosti

LC06027, projekt VaV

Název: Univerzitní výzkumné centrum - Česká myelomová skupina (Akronym: LC MGUS)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Univerzitní výzkumné centrum - Česká myelomová skupina (URC - CMG)

MSM0021622415, záměr

Název: Molekulární podstata buněčných a tkáňových regulací

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Molekulární podstata buněčných a tkáňových regulací

Citovat

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Petr KUGLÍK, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ a Roman HÁJEK. Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade). In Hematologica/The Hematology Journal. Volume 92, no. 6 supplement. Pavia, Italy: Ferrata-Storti Foundation, 2007, s. 165-165. ISSN 0390-6078.

@inproceedings{726964,
   author = {Němec, Pavel and Grešliková, Henrieta and Zaoralová, Romana and Filková, Hana and Kuglík, Petr and Oltová, Alexandra and Pour, Luděk and Adam, Zdeněk and Křivanová, Andrea and Krejčí, Marta and Hájek, Roman},
   address = {Pavia, Italy},
   booktitle = {Hematologica/The Hematology Journal},
   edition = {Volume 92, no. 6 supplement},
   keywords = {multiple myeloma; 1q21 amplifiaction; Velcade; fluorescence in situ hybridisation; DNA probe},
   language = {eng},
   location = {Pavia, Italy},
   pages = {165-165},
   publisher = {Ferrata-Storti Foundation},
   title = {Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)},
   year = {2007}
}

TY  - JOUR
ID  - 726964
AU  - Němec, Pavel - Grešliková, Henrieta - Zaoralová, Romana - Filková, Hana - Kuglík, Petr - Oltová, Alexandra - Pour, Luděk - Adam, Zdeněk - Křivanová, Andrea - Krejčí, Marta - Hájek, Roman
PY  - 2007
TI  - Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)
PB  - Ferrata-Storti Foundation
CY  - Pavia, Italy
KW  - multiple myeloma
KW  - 1q21 amplifiaction
KW  - Velcade
KW  - fluorescence in situ hybridisation
KW  - DNA probe
N2  - i) Introduction: The aim of this study is to investigate if Bortezomib (Velcade) is able to antagonize the impact of negative cytogenetic prognostic markers. We have focused on four chromosomal aberrations known as negative prognostic factors in multiple myeloma (MM) treated by conventional or myeloablastive treatment: deletion of RB gene (13q14), deletion of p53 (17p13), amplification of CKS1B gene (1q21) and translocation t(4;14). ii) Material and Methods: We have identified monotypic plasma cells and studied chromosomal aberrations by cytoplasmic light-chain fluorescence in situ hybridization (cIg-FISH) technique. Up-to-date group of 18 patients (pts.) has following characteristic: 67% of men, median age 62,5 years (44,4-77,9). 50% (9 pts.) were in stage IIIA, 28% (5 pts.) in IIA and 22% (4 pts.) in IA. 61% (11 pts.) were in first relapse, 22% (4 pts.) were in second relapse. The others 17% (3 pts.) were in third relapse. Treatment with Velcade based regimens was continued for up to 8 cycles in 66 % pts. (12/18). ii) Preliminary results: Cytogenetic findings: Deletion of RB gene was found in 8/16 (50%) pts., t(4;14) in 8/15 (53%) pts., deletion of p53 gene in 7/15 (47%) cases and amplification of CKS1B gene in 10/15 pts. (66%). Overall Response (OR) was 39% (0% CR, 11% VGPR, 28% PR). OR was not higher in pts. with cytogenetic findings for all aberration types except t(4;14): OR was 38% vs. 38% for pts. with vs. without deletion of RB gene; 63% vs. 14% for t(4;14) (p=0,240); 29% vs. 50% for deletion of p53 and 40% vs. 40% for amplification of CKS1B. Further, Velcade based therapy showed comparable TTP, DOR and OS in pts. with or without cytogenetic aberations including t(4;14). iv) Preliminary conclusions: We have found no significant difference when compared positivity vs. negativity of each cytogenetic aberration (including t(4;14)) for OR, TTP, DOR, PFS, and OS. This should have been caused by small size of our sample. It is possible that Velcade antagonizes the negative prognostic value of studied cytogenetic findings in MM. Supported by Myeloma Basic Research Centre Brno MU (LC 06027) and by grant from Ministry of Educations MSM0021622415.
ER  -

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Petr KUGLÍK, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ a Roman HÁJEK. Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade). In \textit{Hematologica/The Hematology Journal}. Volume 92, no. 6 supplement. Pavia, Italy: Ferrata-Storti Foundation, 2007, s.~165-165. ISSN~0390-6078.

Podrobný výpis o publikaci